文献速递肝病消化道肿瘤与早癌

白蛋白-胆红素分级揭示HIV相关肝细胞癌中肝脏储备功能与免疫功能障碍的预后关系

The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2017-10-16

该研究基于9国44中心387例HIV相关肝细胞癌患者的多中心回顾性队列,评估白蛋白-胆红素(ALBI)分级对总生存的预测价值。ALBI 1/2/3级中位生存分别为97、17、6个月(P<.001),更高级别与更低CD4计数和更高HIV病毒载量相关。

要点

  • ALBI分级可区分HIV相关肝细胞癌患者的中位生存:1级97个月、2级17个月、3级6个月(P<.001)。
  • ALBI分级越高级,CD4计数越低(1/2/3级分别为464/373/288 cells/mm3)。
  • ALBI分级越高级,HIV病毒载量越高(1/2/3级分别为3.337/8.701/61.845 copies/mL,P<.001)。

核心结论

  • 在这项大型多中心回顾性研究中,ALBI分级凸显了肝脏储备功能与免疫功能障碍之间的相互作用是HIV相关肝细胞癌的预后决定因素。

研究设计与样本

  • 多中心回顾性研究,纳入来自9个国家44个中心的HIV相关肝细胞癌患者,排除接受肝移植者,采用单因素和多因素分析评估ALBI分级对总生存的预测价值。

主要发现

  • 共纳入387例患者,以HCV合并感染为主(78%),BCLC分期A=33%、B=18%、C=37%、D=12%。
  • 确诊肝细胞癌时,84%的患者已接受抗逆转录病毒治疗,中位治疗时长8.8年。
  • ALBI 1级中位生存97个月(95%CI 13-180个月),2级17个月(95%CI 11-22个月),3级6个月(95%CI 4-9个月),P<.001。
  • ALBI分级越高级,CD4计数越低(1/2/3级分别为464/373/288 cells/mm3),HIV病毒载量越高(1/2/3级分别为3.337/8.701/61.845 copies/mL,P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of liver-related mortality in people living with HIV, where co-infection with hepatotropic viruses accelerates the course of chronic liver disease. AIM: To evaluate whether the albumin-bilirubin (ALBI) grade, a more accurate marker of liver dysfunction in HCC, might identify patients with progressive liver dysfunction in the context of HIV/hepatitis co-infection. METHODS: Using uni- and multi-variable analyses, we studied the albumin-bilirubin grade as a predictor of overall survival (OS) in a large, multi-center cohort of patients with HIV-associated HCC recruited from 44 centres in 9 countries within the Liver Cancer in HIV study group. Patients who underwent liver transplantation were excluded. RESULTS: A total of 387 patients, predominantly HCV co-infected (78%) with balanced representation of all Barcelona Clinic Liver Cancer (BCLC) stages (A = 33%, B = 18%, C = 37%, D = 12%) were recruited. At HCC diagnosis, 84% had been on anti-retrovirals for a median duration of 8.8 years. The albumin-bilirubin grade identified significant differences in median survival of 97 months for grade 1 (95% CI 13-180 months), 17 months for grade 2 (95% CI 11-22 months) and 6 months for grade 3 (95% CI 4-9 months, P < .001). A more advanced albumin-bilirubin grade correlated with lower CD4 counts (464/373/288 cells/mm3 for grades 1/2/3) and higher HIV viraemia (3.337/8.701/61.845 copies/mL for grades 1/2/3, P < .001). CONCLUSIONS: In this large, multi-center retrospective study, the albumin-bilirubin grade highlights the interplay between liver reserve and immune dysfunction as prognostic determinants in HIV-associated HCC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pinato DJ, Sharma R, Citti C, et al. The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. Aliment Pharmacol Ther. 2017. PMID: 29034998. doi:10.1111/apt.14356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。